The effect of Aspirin in preventing preeclampsia
Phase 2
- Conditions
- Pre-eclampsia.Pre-eclampsia
- Registration Number
- IRCT20220410054469N1
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 216
Inclusion Criteria
Pregnant women at 12-20 weeks of gestation at high risk for Preeclampsia.
Exclusion Criteria
Patients who find it difficult to follow a regular pattern of medication.
Patients with heart, liver, thyroid, peptic ulcer diseases and bleeding disorder.
Patients with a history of asthma, aspirin sensitivity, and the presence of major fetal disorders.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of Preeclampsia. Timepoint: From 12-20 to 36 weeks of pregnancy. Method of measurement: Mercury sphygmomanometer / laboratory abnormalities (including doubling of liver enzymes, doubling of serum creatinine and drop in platelets below 100,000).
- Secondary Outcome Measures
Name Time Method Type of delivery (cesarean section or vaginal). Timepoint: Time of delivery. Method of measurement: Based on medical file and disease progression.;Term or preterm delivery. Timepoint: Time of pregnancy termination. Method of measurement: Based on medical file and disease progression.